Fractyl Health, Inc.GUTS

Fractyl Health, Inc. filed its most recent 10-Q on 15 July 2026 and the numbers tell a story of profit on paper and cash burn in reality: the company reported $9.2 million in net income for the quarter ending 31 March 2026, against a $20.8 million operating loss and $22.5 million in negative operating cash flow. Cash and equivalents stood at $63.2 million, but total liabilities reached $78.0 million and shareholders’ equity was just $21.4 million, a structure that leaves little room for error. Diluted earnings per share came in at $0.06, produced by 158.5 million shares outstanding-hardly the stuff of scale. (source: FRACTYL HEALTH, INC., 10-Q for the period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1572616/000119312526303948/guts-20260715.htm)

What Fractyl actually sells is a set of metabolic therapeutics aimed at the duodenum and pancreas, organs it casts as root causes of obesity and type 2 diabetes. Its lead product, Revita, is an endoscopic duodenal modulation device under pivotal trial, while Rejuva is a preclinical AAV gene-therapy platform designed as a one-time treatment for islet enhancement. The company markets these as “major advances,” but only Revita has reached human testing-and even there, results are interim. (source: Fractyl Health, Our Platforms, https://www.fractyl.com/our-platforms/; Rejuva product page, https://www.fractyl.com/our-platforms/rejuva/)

The 15 July 2026 press release trumpets positive one-year data from the REMAIN-1 Midpoint Cohort, claiming durable weight maintenance after GLP-1 discontinuation and “clinically meaningful and commercially attractive” effect sizes. The release and accompanying conference-call slide deck tout a mild, periprocedural safety profile and no device-related serious adverse events, which is encouraging for a still-unapproved device. Yet the Midpoint Cohort is a subset of a pivotal program, not a label-ready dataset, and the company’s research tab hit $15.6 million in the quarter-money that hasn’t yet produced an approved revenue stream. (source: Fractyl Health press release dated 15 July 2026, https://www.sec.gov/Archives/edgar/data/1572616/000119312526303948/guts-ex99_1.htm; Conference Call Presentation dated 15 July 2026, https://www.sec.gov/Archives/edgar/data/1572616/000119312526303948/guts-ex99_2.htm)

Fractyl’s media kit is a glossy folder of logos, brochures, and fact sheets, but it contains no revenue, patient, or procedural volume figures-only download links and contact emails. The kit’s existence is less a sign of commercial traction and more a reminder that the company is still selling a vision while the balance sheet sells the reality of modest scale and substantial burn. (source: Fractyl Health media kit, https://www.fractyl.com/media-kit/)

On the governance side, the 8-K filed on 15 July 2026 is heavy on investor optics-highlighting positive data and positioning Revita as a potential “major advance”-and light on hard operational metrics. The filing is typical of a company that prefers headlines to headcounts, a pattern that may keep the story alive in the press but does little to quiet balance-sheet concerns. (source: SEC EDGAR 8-K dated 2026-07-15, https://www.sec.gov/Archives/edgar/data/1572616/000119312526303948/guts-20260715.htm)

The company’s filing index on SEC EDGAR shows a large volume of ownership and submission documents, but none of them reveal customer contracts, payer agreements, or commercial launch timelines-details that would matter far more than polished slide decks once regulators enter the frame. (source: SEC EDGAR filing index for CIK 1572616, https://www.sec.gov/edgar/browse/?CIK=1572616)

For readers tracking the gap between promise and proof, the clearest route is the company’s own filings: quarterly cash burn, rising liabilities, and R&D intensity that hasn’t yet produced a marketed product. Until Revita or Rejuva secures regulatory clearance and commercial traction, the balance sheet remains the only source of truth-and it’s still running a deficit. (source: FRACTYL HEALTH, INC., 10-Q for the period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1572616/000119312526303948/guts-20260715.htm)